Together, these data suggest that targeting the IL-33/Il1rl1 signaling pathway could be a therapeutic strategy for AML through dual inhibition of the LSCs and the inhibitory tumor microenvironment. The gene discussed is IL33; the disease is acute myeloid leukemia.